Combination Antibody Therapy

Global Market Trajectory & Analytics

MCP11165

EXECUTIVE ENGAGEMENTS

OUTREACH

3073
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

554
Interactions with Platform & by Email

PARTICIPANTS

92
Unique # Participated

VALIDATIONS

41
Responses Validated*

COMPETITORS

46
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

104

PAGES

180

EDITION

6

PRICE

USD $4950


  

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Combination Antibody Therapy estimated at US$72.1 Billion in the year 2020, is projected to reach a revised size of US$173.4 Billion by 2027, growing at a CAGR of 13.4% over the analysis period 2020-2027. Chemotherapy/Antibody, one of the segments analyzed in the report, is projected to record a 9.6% CAGR and reach US$76.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antibody/Antibody segment is readjusted to a revised 17.9% CAGR for the next 7-year period.
The Combination Antibody Therapy market in the U.S. is estimated at US$21.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$30.6 Billion by the year 2027 trailing a CAGR of 13% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.
In the global Other Combinations segment, USA, Canada, Japan, China and Europe will drive the 12% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3.8 Billion in the year 2020 will reach a projected size of US$8.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$21 Billion by the year 2027.

SELECT PLAYERS

Amgen, Inc.; Biogen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche AG; Genmab A/S; Novartis AG; Sanofi; Seattle Genetics, Inc.

SEGMENTS

» Application (Lung Cancer, Blood Cancer, Breast Cancer, Other Applications) » Combination (Chemotherapy/Antibody, Antibody/Antibody, Other Combinations) » End-Use (Hospitals, Cancer Research Institutes, Other End-Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Combination Antibody Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Combination Antibody Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for Chemotherapy/Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Chemotherapy/Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Antibody/Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Antibody/Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
USA Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
USA Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Canada Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Canada Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Japan Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Japan Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
CHINA
China Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
China Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
China Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for Combination Antibody Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Combination Antibody Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Europe Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Europe Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
France Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
France Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Germany Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Germany Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Italy Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Italy Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
UK Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
UK Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy/Antibody, Antibody/Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy/Antibody, Antibody/Antibody and Other Combinations for the Years 2020 & 2027
Rest of World Current & Future Analysis for Combination Antibody Therapy by Application - Lung Cancer, Blood Cancer, Breast Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Lung Cancer, Blood Cancer, Breast Cancer and Other Applications for the Years 2020 & 2027
Rest of World Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2020 & 2027
Total Companies Profiled: 46

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com